Pathway to Cures, the venture philanthropy fund of the National Bleeding Disorders Foundation is focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community.  We carry out our work with volunteer expert advisors on our scientific advisory group, investment committee and board of directors.  Today we spotlight our investment committee, our process for determining what is presented to this committee and the criteria used in making NBDF’s Pathway to Cures investments.

NBDF is pleased to inform U.S.-based clinicians and other interested individuals of a new series of virtual educational opportunities organized by our friends at the Irish Haemophilia Society (IHS). The IHS is hosting a series of clinical webinars on key topics developed for healthcare providers practicing in the global bleeding disorders community. The six webinars will be held on Zoom during the months of October, November, and December.

Star Therapeutics recently announced new financing (totaling $125 million) that will help the San Francisco-based biotechnology company continue to develop their investigational von Willebrand disease therapy VGA039. The U.S. Food and Drug Administration granted Fast Track designation to the experimental subcutaneous von Willebrand disease therapy (VWD) in January 2025.